Silence Therapeutics (SLN) Deferred Taxes (2024 - 2025)
Silence Therapeutics (SLN) reported Deferred Taxes of $1000.0 for Q3 2025, down 97.96% on a YoY basis from $49000.0 in Q3 2024, and down 90.0% sequentially from $10000.0 in Q2 2025.
Silence Therapeutics (SLN) Deferred Taxes (2024 - 2025) Analysis & Trends
Silence Therapeutics (SLN) has 2 years of Deferred Taxes data on file, last reported at $1000.0 in Q3 2025.
- For the quarter ending Q3 2025, Deferred Taxes fell 97.96% year-over-year to $1000.0; the trailing twelve-month figure through Dec 2025 stood at $11000.0 (down 98.7% YoY), and the FY2025 full-year result was $11000.0, down 98.7% from the prior year.
- Deferred Taxes slipped to $1000.0 in Q3 2025, from $10000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $324000.0 in Q4 2024 to a low of $1000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Silence Therapeutics | 1.62 Bn | 1.49 Bn | 411,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Dec 31, 2024 | 324,000.00 |
| Sep 30, 2024 | 49,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Mar 31, 2024 | 244,000.00 |